Medical Device News Magazine

Sonara Health Granted Patent For Take-Home Methadone Monitoring System

Revolutionary Monitoring System's Tamper-Evident Label Allows People To More Safely Consume Methadone From Home, Eliminating Daily Clinic Visits

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Sonara Health has been granted a U.S. patent for creating a tamper-evident label that facilitates the safe consumption of methadone at home to treat opioid use disorder and fight America’s opioid crisis.

Sonara Health’s remote medication monitoring system includes a tamper-evident label, a patient-facing web application to guide the patient’s daily consumption of methadone at home and a clinician-facing web application to remotely, asynchronously, observe patients dosing. The Sonara remote medication monitoring system helps eliminate the need for patients to visit a clinic every day, which is often a barrier for people who live far away from clinics or who have jobs and family obligations.

Methadone is among the most effective medications approved by the FDA to treat opioid use disorder.

“In a world where we send billionaires to space in reusable rockets, I thought we ought to be able to create a solution that helps patients with opioid use disorder to get their daily medication in a way that does not disrupt their daily lives, all while preserving the safety and efficacy of a proven delivery system,” said Michael Giles, M.D., and CEO of Sonara Health.

The Mark Cuban-backed health-tech company was designed to improve patient-provider trust and promote access to take-home methadone for opioid treatment programs and their patients. Sonara’s mission is to end the opioid epidemic. Staggering data from the CDC showed over 100,000 people died from drug overdoses last year and about two-thirds of those deaths involved fentanyl or another synthetic opioid.

The Sonara medication monitoring system is simple. The patient scans the QR code on the methadone bottle with their smartphone and follows the steps provided for dosing-at-home. Once scanned and opened, the QR code is voided and the label indicates that it has been opened. The phone’s camera then turns on and a video stream of the patient drinking the methadone is uploaded to the clinician-facing application for the care team to review and ensure proper medication handling.

Early adopters of Sonara include the following opioid treatment programs:

BayMark Health Services, Inc.

BAART, Market Street, San Francisco, CA
BAART, Norwood, Sacramento, CA
HCRC, New Bedford, MA
RSONM, Five Points, Albuquerque, NM (coming soon)
RSONM, Roswell, NM (coming soon)
CODA, Inc.

CODA, Portland, OR
CODA, Seaside, OR
New Season Treatment Centers

Augusta Metro Treatment Center, Augusta, GA

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”